Can I Get Mounjaro in the UK?

Mounjaro, also known as tirzepatide, is an innovative prescription medication that has recently gained attention for its effectiveness in promoting weight loss. Originally developed by pharmaceutical company Eli Lilly as a treatment for individuals with type 2 diabetes, Mounjaro has shown remarkable impact on weight management, potentially revolutionizing obesity treatment.

In fact, some media outlets are calling it the ‘King Kong’ of weight loss.

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the prescription of Mounjaro (tirzepatide), for weight loss and weight management in adults aged 18 and over as of November 2023.

Mounjaro is now authorised for adults with a BMI above 30, as well as those with a BMI between 27-30k who also have weight-related health problems such as prediabetes, high blood pressure, high cholesterol, or heart problems.  

Understanding Mounjaro

It is an injectable weight health therapy administered once-weekly containing the active ingredient tirzepatide. 

Mounjaro has two incretin hormones and it is classified as a ‘dual-agonist’.  This double agonist approach seems to cause people who use Mounjaro weekly injections to lose even more weight than those who use a single-agonist medication.  These receptors stimulate hormones that control blood sugar levels and reduce appetite, triggering weight loss.  The receptors are known as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

Bodyline is at the forefront of providing the latest obesity treatment options, as we continue to offer safe, effective, and sustainable medical weight loss programmes.

The Potential of Mounjaro in Weight Loss

Clinical trials have demonstrated promising results for Mounjaro in terms of weight loss and blood sugar control. In a meta-analysis of 22 trials, researchers compared Mounjaro with other GLP-1 receptor agonists semaglutide and liraglutide. The findings revealed that tirzepatide (Mounjaro) was superior to both semaglutide (branded as Ozempic or WeGovy) and liraglutide (branded as Saxenda) in controlling blood sugar levels and promoting weight loss.

Individuals taking Mounjaro experienced greater weight loss compared to those on semaglutide or liraglutide weekly injections.

Mounjaro in the UK

As of November 2023, Mounjaro is now approved by the MHRA to be prescribed as a treatment of obesity in the UK to those who are eligible for the medication. 

Guidance for the prescription of Mounjaro in weight health management is similar to the NICE guidance for WeGovy, being made available to those with a BMI of over 30, or those with a BMI of above 27 and suffering with weight related health problems.

Approval is very new, but we will be keeping our clients updated on the latest news in obesity treatments in the UK.


Contact Bodyline today to find out more about our safe and effective weight loss programmes and range of treatment options.

"*" indicates required fields

By submitting this form you agree to the Bodyline privacy policy.
This field is for validation purposes and should be left unchanged.

The Importance of Medical Supervision

It is crucial to note that upon its approval, Mounjaro, like any prescription medication, should only be used under proper medical supervision. Weight loss medications are most effective when integrated into a fully supported programme that includes a reduced-calorie diet, increased physical activity, and lifestyle modifications.

At Bodyline, we take a comprehensive approach to weight loss, considering each individual’s unique needs and goals. Our healthcare professionals thoroughly assess medical history, current medications, and underlying health conditions to determine the most suitable weight loss medication, whether it be Mounjaro, WeGovy, or another option. We provide ongoing monitoring and support to ensure the safety and effectiveness of the treatment.

We’ve helped over 100,000 people reach their wellness goals, and as new medical weight loss treatments become available in the UK we will be at the forefront of the latest, safest, and most effective options for our clients.

The Journey to Successful Weight Loss

Weight loss is a journey that requires dedication and a multifaceted approach. While Mounjaro could be a valuable tool in achieving weight loss goals, it is essential to prioritize healthy eating, regular physical activity, and lifestyle modifications as part of the overall plan. Medical weight loss injections like Mounjaro are there when diet and exercise alone are not producing the desired results.

If you are interested in exploring weight loss treatments like Mounjaro as a potential solution for your weight management, Bodyline is here to help. Our experienced healthcare professionals can provide the guidance and support you need to embark on a successful weight loss journey. Contact us today at 0800 995 6036 or through our contact form.

Remember, successful weight loss is within reach, and with the right support and tools, you can achieve your goals and improve your overall well-being.

Related blog posts

By now we should all have heard of the incredible weight loss results from GLP-1 receptor agonist medications and their ever-growing popularity. All over the UK, people are searching for access to ‘game changing’ medications to solve their weight problems. Searches for semaglutide, tirzepatide and liraglutide (brand names WeGovy/Ozempic, Mounjaro, and Saxenda respectively) have increased dramatically in the past year, and interest continues to rise. That’s because for the first time ever, there seems to be a potential long-term solution to the obesity epidemic that has afflicted the world over the past 30 years.
If you're on a weight loss journey and are prescribed medication to aid in this process, it's essential to manage your medication intake effectively during Ramadan to ensure both your health and adherence to religious obligations.
Despite the enormous popularity of WeGovy and its incredible impact on weight loss, a shortage of the injectable weight loss therapy has been ongoing in recent months. The semaglutide-containing injection has been dubbed “game-changing” for the treatment of obesity, and demand has been high, but manufacturer Novo Nordisk has struggled to keep up and has only released limited stock.

CONTACT US TODAY

Contact Bodyline to find out more how we can treat and support you to improve your health and wellbeing.

"*" indicates required fields

Select the Bodyline treatment that you would like to discuss*
By submitting this form you agree to the Bodyline privacy policy.